Research Paper Volume 12, Issue 24 pp 26199—26220
Ring finger protein 2 promotes colorectal cancer progression by suppressing early growth response 1
- 1 Department of Orthopedics, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China
- 2 Department of Anorectal Surgery, Tianjin Union Medical Center, Nankai University Affiliated Hospital, Tianjin 300013, China
- 3 Urology Department of No. 989 Hospital, Joint Logistics Support Force of PLA, Luoyang 471000, China
- 4 Department of Gastroenterology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China
- 5 State Key Laboratory of Cancer Biology, Department of Immunology, Fourth Military Medical University, Xi’an 710032, China
- 6 Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China
- 7 Department of Urology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China
- 8 Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China
Received: November 25, 2019 Accepted: November 11, 2020 Published: December 19, 2020
https://doi.org/10.18632/aging.202396How to Cite
Abstract
Ring finger protein 2 (RNF2) is an important component of polycomb repressive complex 1. RNF2 is upregulated in many kinds of tumors, and elevated RNF2 expression is associated with a poor prognosis in certain cancers. To assess the function of RNF2 in colorectal cancer, we examined RNF2 protein levels in 313 paired colorectal cancer tissues and adjacent normal tissues. We then analyzed the association of RNF2 expression with the patients’ clinicopathologic features and prognoses. RNF2 expression was upregulated in colorectal cancer tissues and was associated with the tumor differentiation status, tumor stage and prognosis. In colorectal cancer cell lines, downregulation of RNF2 inhibited cell proliferation and induced apoptosis. Gene microarray analysis revealed that early growth response 1 (EGR1) was upregulated in RNF2-knockdown cells. Knocking down EGR1 partially reversed the inhibition of cell proliferation and the induction of apoptosis in RNF2-knockdown cells. RNF2 was enriched at the EGR1 promoter, where it mono-ubiquitinated histone H2A, thereby inhibiting EGR1 expression. These results indicate that RNF2 is oncogenic in colorectal cancer and may promote disease progression by inhibiting EGR1 expression. RNF2 is thus a potential prognostic marker and therapeutic target in colorectal cancer.